Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MEDI0639||MEDI-0639||DLL4 Antibody 6||MEDI0639 is a monoclonal antibody which binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation, angiogenesis, and tumor growth (PMID: 22679110).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MEDI0639||Phase I||Actionable||In a Phase I trial, MEDI0639 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr 3024)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01577745||Phase I||MEDI0639||A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors||Completed|